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Smyd2 lysine methyltransferase regulates monomethylation of histone and
nonhistone lysine residues using S-adenosylmethionine cofactor as the
methyl donor. The nonhistone interactors include several tumorigenic tar-
gets, including p53. Understanding this interaction would allow the struc-
tural principles that underpin Smyd2-mediated p53 methylation to be
elucidated. Here, we performed l-second molecular dynamics (MD) simu-
lations on binary Smyd2-cofactor and ternary Smyd2-cofactor-p53 peptide
complexes. We considered both unmethylated and monomethylated p53
peptides (at Lys370 and Lys372). The results indicate that (a) the degree of
conformational freedom of the C-terminal domain of Smyd2 is restricted
by the presence of the p53 peptide substrate, (b) the Smyd2 C-terminal
domain shows distinct dynamic properties when interacting with unmethy-
lated and methylated p53 peptides, and (c) Lys372 methylation confines the
p53 peptide conformation, with detectable influence on Lys370 accessibility
to the cofactor. These MD results are therefore of relevance for studying
the biology of p53 in cancer progression.
1. Introduction
Smyd2 is a member of five lysine methyltransferases
constituted by a suppressor of variegation, enhancer of
zeste, trithorax (SET) domain (InterPro ID
IPR001214), intercalated by a myeloid-nervy-DEAF1
(MYND) zinc binding domain (InterPro ID
IPR002893). Smyds catalyze the monomethylation of
histone and nonhistone lysine residues, using the S-
adenosylmethionine methyl donor cofactor (AdoMet/
SAM) and releasing the product S-adenosylhomocys-
teine (AdoHcy/SAH) (Spellmon et al., 2015).
Smyd2 targets H3 (Lys4, Lys36), but its peculiarity
among the Smyds lies in the vast broad spectrum of
nonhistone targets that comprehend around twenty
proteins, such as p53 (Lys370), retinoblastoma
(Lys860), estrogen receptor ERa (Lys266), PARP1
(Lys528), HSP90 (Lys531, Lys574), and, recently,
BMPR2 (Brown et al., 2006; Foreman et al., 2011;
Gao et al., 2017; Gottlieb et al., 2002; Hamamoto
Abbreviations
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et al., 2004; Van Aller et al., 2012). Recent proteomics
studies have identified several additional potential
Smyd2 substrates (Ahmed et al., 2016; Olsen et al.,
2016).
Another methyltransferase, Set9, also targets p53 (at
Lys372) (Chuikov et al., 2004). This may be of partic-
ular interest in DNA damage response (Nemajerova
et al., 2018; Parrales et al., 2018), cell cycle arrest
(Engeland, 2018; Wu and Prives, 2018), tumor sup-
pression (Charni et al., 2018; Kaiser and Attardi,
2018) and in particular in cancer progression (Aubrey
et al., 2018; Baugh et al., 2018; Kim and Lozano,
2018), when considering the pivotal role of p53 in
these molecular mechanisms (Furth and Aylon, 2017;
Furth et al., 2018; Sullivan et al., 2018). Consequently,
the interaction between p53 and Smyd2 could be of
high relevance. Methylation of Lys370 p53 by Smyd2
reduces its binding efficiency to promoter genes,
thereby repressing p53 transcriptional activity (Huang
et al., 2006). The opposite functional effect is observed
when Set9 methylates Lys372, with an increase of sta-
bility and activity of p53 (Marouco et al., 2013). A
fine tuning of p53 transcriptional activity, therefore, is
obtained via alternative methylation by Smyd2 on
Lys370 and Set9 on Lys372.
Different in vivo studies have demonstrated the role
played by Smyd2 in cancer initiation and progression
(Bagislar et al., 2016; Reynoird et al., 2016). In line,
downregulation of Smyd2 by small interfering RNA in
cells promotes p53-mediated apoptosis, while its over-
expression in esophageal squamous cell carcinoma is
inversely correlated with patients survival rate
(Komatsu et al., 2009). Smyd2 is also highly expressed
in pediatric acute lymphoblastic leukemia, and higher
expression level is correlated with bad prognosis
(Sakamoto et al., 2014). The important role played by
Smyd2 in cancer biology has spurred the development
of cell-active inhibitors (Ferguson et al., 2011; Nguyen
et al., 2015; Sweis et al., 2015). Recent evidences, how-
ever, show no impact of Smyd2–3 inhibition on cancer
cell proliferation in vitro (Thomenius et al., 2018).
Smyd2 and 3, therefore, could play a role in other
steps of oncogenesis such as an early initiation step of
oncogenesis, or in cell growth relevant only in vivo,
like the regulation of the tumor microenvironment,
angiogenesis, or immune evasion (Mazur et al., 2014;
Thomenius et al., 2018). Further studies on the func-
tional mechanism of Smyds are clearly needed.
From a structural point of view, the N- and C-ter-
minal domains of Smyd2 form a clamp in which the
substrate is inserted in a position in which it can
receive the methyl group from AdoMet (Fig. 1A,B).
Recently, we carried out a molecular dynamical study
of Smyd2, highlighting its differential substrate crevice
characteristics as compared to Smyd3 (Chandramouli
and Chillemi, 2016; Chandramouli et al., 2016). From
these studies, a critical role of the Smyds C-terminal
domain emerges that orchestrates the catalytic cycle.
Previously, we have also performed dynamic studies
on p53 in monomeric (Chillemi et al., 2013) and tetra-
meric (Chillemi et al., 2017; D’Abramo et al., 2016)
conformation, showing a relevant induced-fit interac-
tion of the p53 C-terminal domain with the DNA-
binding domain. Here, we have performed l-second
molecular dynamics (MD) simulations to further
understand the underlying molecular events regulating
the Smyd2 catalytic cycle.
2. Materials and methods
2.1. Model generation and simulation protocol
Atomic coordinates for binary Smyd2-AdoMet (PDB
ID: 3TG4) and ternary Smyd2-AdoHcy-p53 (PDB ID:
3TG5) complexes were extracted from better resolved
X-ray crystallographic structures from PDB (Wang
et al., 2011). Histidine protonation states were
assigned based on the consensus predictions by H++
(v3.1), Protoss and Propka programs (Anandakrishnan
et al., 2012; Bietz et al., 2014; Li et al., 2005). All sim-
ulations were performed with AMBER package (v.14)
treating the protein with ff14SB forcefield (Hornak
et al., 2006). Parameters for AdoMet and AdoHcy
were adapted from Amber ff10 forcefield and a previ-
ous study (Hornak et al., 2006; Markham et al., 2002;
Wang et al., 2000). The partial charges were obtained
after a geometry optimization at HF/6-31G* level of
theory using Gaussian (Gaussian 09; Gaussian Inc.,
Wallingford, CT, USA), followed by fitting the electro-
static potential with the restrained electrostatic poten-
tial procedure using RED tools (Bayly et al., 1993;
Vanquelef et al., 2011). Dihedral restraints were
applied during optimization to retain enzyme-bound
conformations of AdoMet and AdoHcy. Zinc ions and
the associated protein residues coordinated to the ion
were treated with ZAFF parameters (Li et al., 2013;
Peters et al., 2010). The starting structures were placed
in a cubic box of TIP3P water model that extended up
to ~ 15 A from solute surface (Jorgensen et al., 1983).
Additional counterions were added to achieve charge
neutrality. All systems were subjected to elaborate
equilibration as detailed in our previous reports
(Chandramouli and Chillemi, 2016; Chandramouli
et al., 2016). Production simulations were performed
in NVT ensemble for 1 ls for each system, and
1451Molecular Oncology 13 (2019) 1450–1461 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
B. Chandramouli et al. Smyd2-p53 interplay
snapshots in the trajectory were saved at intervals of
10 ps. The simulation conditions included periodic
boundary conditions, constraining covalent heavy
atom–hydrogen bonds via SHAKE (Ryckaert et al.,
1977), 2 fs time step for numerical integration, PME
method for calculating long-range electrostatic interac-
tions (Darden et al., 1993), 12 A cutoff for short-range
nonbonded interactions, temperature regulation with
Langevin coupling using a collision frequency of
2.0 ps1 (Izaguirre et al., 2001).
2.2. MD Trajectories analysis
For all root-mean-square (RMS) fitting, the respective
X-ray structures were used as the reference. Unless sta-
ted otherwise, reference to backbone means Ca, C, N
atoms. Dynamic cross-correlation matrix was com-
puted considering the backbone coordinates as fol-
lows,
Cij ¼ hDriDrjiﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
hDr2i i
p ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
hDr2j i
q
where Dri is the displacement of ith atom from the
mean position and < > represents the ensemble average
over the analyzed portion of trajectory. Interaction
energies and atom distances were calculated on the last
900 ns portion of the trajectories considering a snap-
shot every 100 ps (for a total of 9000 analyzed confor-
mations). Principal component analysis (PCA) was
performed by diagonalizing the covariance matrix
obtained from atomic fluctuations after removing
Fig. 1. Smyd2 structure and simulated complex models. X-ray structures of binary Smyd2-AdoMet (A) and ternary Smyd2-AdoHcy-p53 (B)
complex. Smyd2 N- and C-terminal domains are shown as ribbons in gray and cyan. AdoMet and AdoHcy are represented in blue and
green, respectively. Zinc ions are shown as orange spheres with coordinated protein residues in magenta. The p53 peptide is shown as
yellow tube. (C) Schematic view of the simulated models. The sequence numbering of the p53 peptide is given for clarity. The Data color
code adopted in all the following graphs is also shown.
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rotations and translations by fitting the snapshots onto
the X-ray structure (Amadei et al., 1993). To this pur-
pose, a concatenated artificial trajectory was generated
with snapshots from respective simulations obtained at
100 ps intervals over the last 900 ns. This permitted to
project the frames yielded from the independent simu-
lations on a common plane. Geometric angles (Chan-
dramouli and Chillemi, 2016 for definitions) were
calculated after fitting the trajectories over the N-ter-
minal domain of the X-ray structures. All above analy-
ses were performed using AMBERTOOLS (v1.5), GROMACS
utilities (v.5.0.7) or codes in-house written using
MDAnalysis (Michaud-Agrawal et al., 2011; Roe and
Cheatham, 2013; Van Der Spoel et al., 2005). Graphi-
cal plots and figures were generated with Matplotlib
library and UCSF Chimera (Hunter, 2007; Pettersen
et al., 2004). Clustering was performed using hierarchi-
cal density-based method as implemented in hdbscan
library (Campello et al., 2013; Campello et al., 2015;
McInnes et al., 2017).
3. Results and Discussion
In order to improve our understanding of the Smyd2
catalytic cycle, here we carried out l-second MD simu-
lations of the following systems (see Fig. 1): Smyd2 in
complex with AdoMet cofactor (Model-A); Smyd2-
AdoMet-p53 peptide (unmethylated) complex (Model-
B); Smyd2-AdoHcy-p53 peptide (methylated at
Lys370) complex (Model-C); and Smyd2-AdoMet in
complex with the p53 peptide methylated at Lys372
(Model-D).
In the following, we report structural elements that
describe the conformational rearrangements and flexi-
bility of Smyd2 and p53 peptides; the global motion of
Smyd2 protein associated in its binary and ternary
states, and finally, we highlight the dynamical charac-
teristics of unmethylated and methylated p53 peptides
as they bound to Smyd2 (see Fig. S1). The following
color code is adopted in the figures: Model-A (black),
Model-B (gray), Model-C (red), and Model-D (blue),
as reported also in Fig. 1C.
3.1. Peptide substrates restrict the motion of
Smyd2 C-terminal domain
The structural rearrangements during the simulation
with respect to the starting X-ray configuration were
monitored via estimating the backbone RMSD for
Smyd2 and p53 peptides (Fig. S2). The time evolution
of RMSD values shows a higher deviation in the bin-
ary system (Model-A) compared to the ternary systems
(Fig. S2A), and the RMSD values are uniformly
distributed around a higher mean of 3.2 ( 0.4). This
indicates a larger structural relaxation in the absence
of the substrate peptide. Among the ternary systems,
RMSD values of Model D (p53 peptide with methy-
lated Lys372) show a remarkable stability, while the
two models B and C (unmethylated lysines and methy-
lated at Lys370, respectively) fluctuate during the sim-
ulations up to 3 A. The mean RMSD for models B–D
are 2.0 ( 0.3), 1.9 ( 0.5), and 1.4 ( 0.2) A, respec-
tively. First, there results already show the great influ-
ence played by the bound p53 peptide on the overall
dynamics of Smyd2, including the capability to dis-
criminate between the two methylated lysines.
Further, the distribution of RMSD values calculated
separately for Smyd20s N- and C-terminal domains
(hereinafter, NTD and CTD) shows a high overlap for
the NTD across the all simulated models (Fig. S2B).
For the CTD, interestingly, the RMSD distribution in
the binary case is shifted toward higher values with
respect to the ternary ones. Overall, these results imply
that the larger RMS deviations observed in the binary
simulation are driven by the structural relaxation of
the CTD, while this remains relatively restricted in the
ternary ones (i.e., in the presence of the substrate pep-
tides). Time-evolved RMSD variations for the p53
peptides show a stable profile for the methylated at
Lys372 system (Model-D; Fig. S2C). In contrast, more
fluctuations are observed for the unmethylated peptide
(Model-B) and the p53 methylated at Lys370 (Model-
C). All the following analyses were restricted to the
last 900 ns of the trajectories.
To identify the flexible segments of Smyd2 protein
and p53 peptides, we calculated the per-residue aver-
aged backbone root-mean-square fluctuation (RMSF)
(Fig. 2A). In absence of the p53 peptides, the most
mobile regions are located around the first antiparallel
a-helices of the C-terminal domain (black asterisks). In
the ternary systems, additional peaks are observed for
models C (residue 157, red asterisk) and D (residue 10,
blue asterisk), in the NTD. These residues belong to a
small solvent-exposed loop at the N-terminal segment
and MYND domain of Smyd2, afar sites from the
peptide-bound crevice.
The RMSF plots for the p53 peptides indicate a
higher flexibility at the terminal ones (Fig. 2B). The
flexibility is especially enhanced at the C-terminal end
of the peptide, which forms direct contacts with Smy-
d20s CTD. The p53 peptide methylated at Lys370 exhi-
bits higher mobility compared to the unmethylated or
methylated at Lys372 one. The localized methylation
effect on the residue flexibility was also examined by
RMSF estimations at time windows of 30 ns. The
obtained range of RMSF, depicted in Fig. S3, suggests
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that the methylation at Lys370 (position 0) or Lys372
(position +2) enhances the flexibility at the nearby sites
( 1 residues) in comparison with the unmethylated
one. This effect is slightly higher for the Lys370
methylation.
3.2. C-terminal domain exhibits different
dynamical response to unmethylated and
methylated p53 peptides
To characterize the global dynamics of Smyd2 across
the different simulations, the dynamic residue cross
correlation (DCC) and PCA were performed consider-
ing the backbone atoms. The DCC highlights the
inter-residue communications, even at long range. Pos-
itive and negative correlation (Cij) values indicate in-
phase and out-of-phase motions of a residue pair (ri
and rj). PCA permits to describe the complex protein
motion in a subset of subspaces that largely accounts
for most of the motional variance, as defined by the
corresponding eigenvectors.
The DCC matrix obtained for models B and C is
shown in Fig. 3, and the matrix for models A and D
is reported in Fig. S4. Inspection of the matrices
reveals noticeable differences in interdomain communi-
cations between N- and C-terminal domains. In
Model-C, the CTD exhibits strong anticorrelation
movements against the NTD segments. This anticorre-
lation is highly reduced in Model-B, containing the
unmethylated peptide (Fig. 3A, compare blue regions
in upper and lower triangles). Structural depiction of
strong Cij values highlights that the interdomain anti-
correlations in Model-C span across different segments
of both the domains (Fig. 3B). In Model-B, the anti-
correlations are restricted between the first antiparallel
a-helices of the CTD and MYND segment of the
NTD (Fig. S4). Methylation of Lys370, therefore, has
as a consequence the establishment of new long-range
interactions, particularly between NTD and CTD.
The DCC matrix for Model-A (Fig. S4A, upper tri-
angle) shows strong anticorrelations between the two
domains. This result is also consistent with the previ-
ously reported observation from sub-l-second sam-
pling for the model (Chandramouli and Chillemi,
2016). Smyd2 in Model-D exhibits lower interdomain
anticorrelations (Fig. S4A, lower triangle), similar to
Model-B (Fig. 3C, upper triangle). The structural
depiction reveals again the presence of the correspond-
ing correlations only between a fewer residues in the
first a-helix of the CTD and those in the MYND seg-
ment of the NTD. Methylation of Lys372 is not cap-
able, therefore, to activate long-range interactions, and
in this respect, this system is similar to the unmethy-
lated p53 peptide. At variance, several long-range
interactions are present in absence of the p53 peptide.
In order to further characterize the anticorrelated
motions highlighted by the DCC analysis, we defined
and analyzed two geometric descriptors, the open and
slide angles, whose distribution is reported in Fig. 4.
These highlight a sort of hingelike motion of the CTD
with respect to the NTD counterpart. In the binary
case (Model-A), the distribution of both angles is well
Fig. 2. Residue flexibility in the simulated models. Per-residue averaged backbone RMSF as a function of residue index. (A) RMSF for
Smyd2 ignoring the terminal ones for models A–D (refer Fig. 1C) in black, gray, red, and blue, respectively. Peak regions are indicated with
asterisks. Inset plot indicates the difference RMSF values for ternary systems with respect to the binary system. Shaded portion represents
the N-terminal domain. (B) RMSF for p53 residues in ternary systems (refer Fig. 1c for residue index definition).
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shifted from the X-ray configuration and also above
the ternary ones (models B–D). The mean values of
the absolute difference in the open angles from the X-
ray structure for models A–D were 9.7 ( 2.7), 4.3
( 2.1), 2.9 ( 1.8), and 4.2 ( 2.0) degree. Similarly,
the mean values for the slide angles were 13.7 ( 4.9),
6.1 ( 3.5), 3.8 ( 2.9), and 2.7 ( 1.9) degree.
To compare the Smyd20s dynamics across the simu-
lations, PCA was performed on a concatenated trajec-
tory that included snapshots from all the models.
Projection of trajectory snapshots onto the subspace
defined by first three eigenvectors that explains ~ 70%
of motional variance is reported in Fig. S5. It is clear
that the dynamical basin of Model-A (binary system)
is well separated from the ternary ones (Fig. S5A,B).
Further, the larger deviation in mean projection along
the corresponding eigenvectors confirms its higher flex-
ibility compared to the ternary ones (Fig. S5C).
Among the ternary ones, projections of Model-D over-
lap yet span a restricted basin compared to the other
ternary systems (models B and C).
3.3. p53 methylation at Lys372 has notable
effects on the accessibility of Lys370 to the
cofactor
We characterized the dynamical features of bound p53
peptides in the ternary complexes by examining the
interaction profile, geometric, and structural parame-
ters (Fig. 5). Interaction energy between the p53
methylation sites (Lys370/Lys372  1 residue) and
Smyd2 residues within 15 A was estimated via electro-
static and vdW terms and represented as boxplots
(Fig. 5A). Methylation at Lys370 or Lys372 does not
have great influence on the electrostatic interactions
(compare gray vs red bars for Lys370 and gray vs blue
bars for Lys372). On the contrary, the vdW interac-
tions are increased as indicated by the reduction by
~ 3.2 and 6 kcalmol1 of the median values (white
line in Fig. 5A) in models C and D, respectively. The
Q1–Q3 quartile range distribution represented in the
boxplot, however, shows that the two distributions are
significantly different only in the case of methylation
Fig. 3. 2D and 3D representations of dynamic cross correlation between protein residues. (A) Dynamic cross correlation matrix for Smyd2
residues for the ternary systems: Model-B containing unmethylated-p53 (upper triangle) and Model-C with methylated-p53 at Lys370 (lower
triangle). (B) Structural mapping of the cross correlation values for Model-B, where Ca pairs having correlations in range 0.7 < Cij < 0.5
are connected by blue springs. (C) Structural mapping of the cross-correlation values for Model-C.
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at Lys372 (model-D vs the unmethylated model-B).
Interaction energies between the complete p53 peptide
and Smyd2 show a similar trend: no distinct difference
in electrostatic interactions except an increase in vdW
interactions as we go from models B to D (Fig. S6A).
Also, in this case, the boxplot distributions for models
D and B are significantly different. Distribution of the
gyration radius reveals that p53 methylated at Lys372
maintains a relatively compact structure as compared
to the unmethylated or methylated p53 at Lys370. This
is also apparent from the time-evolved variations in
gyration radius (Fig. S6B). Further, the PCA and cor-
responding projections along the principal eigenvectors
(Fig. 5C) reveal a restricted conformational basin for
Lys372-methylated p53, which correlates with other
structural characteristics mentioned above.
The accessibility of Lys370, the natural target site
for Smyd2-mediated p53 methylation, to the cofactor
was assessed by calculating the distance between the
amino group of Lys370 and the sulfur atom of Ado-
Met/AdoHcy that acts as the methyl donor (boxplot
representation in Fig. 5D). Lys370 in Model-C is more
accessible than when the target peptide is
Fig. 4. Geometric descriptors characterizing the hinge motion of
the CTD for models A–D in black, gray, red, and blue, respectively
(refer Fig. 2). (A) Definition of open angle along with its distribution
over the last 900 ns. (B) Definition of slide angle and its
corresponding distribution. The dashed line indicates the value for
the X-ray structure.
Fig. 5. p53 interaction profile and conformational dynamics. (A) Boxplot representation of interaction energy (electrostatic and van der Waals
terms in kcalmol1) between the methylation site (i.e., Lys370/Lys372 and  1 adjacent residues) and Smyd2 for models B–D (refer
Fig. 1c) in gray, red, and blue, respectively. (B) Distribution of the gyration radius of p53 peptide during the last 900 ns. (C) Projection of p53
structures along the eigen subspace defined by principal vectors 1–2 and 1–3, respectively. (D) Distance between Lys370 amino group
nitrogen and the sulfur atom of AdoMet or AdoHcy. (E) Superimposition of representative conformers obtained from clustering.
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unmethylated (Model-B). Further, methylation at
Lys372 also influences Lys370 accessibility to the sul-
fur as demonstrated by the increased distance by
~ 1.4 A, even though the difference between the dis-
tance distribution in models D and B is not significant.
These observations correlate with the increased vdW
interactions between the methylated lysines and pro-
tein residues (vida supra).
Biochemical characterization of Smyd2 activity via
steady-state kinetic and product inhibition experiments
has established that Smyd2 operates through a rapid
equilibrium random Bi Bi mechanism (Wu et al.,
2011). The lysine methylation involves a direct nucle-
ophilic attack of the methyl group leaving the AdoMet
by the target amine without the formation of methyl-
protein intermediate (Wu et al., 2011). Hence, a proper
insertion of the target lysine (Lys370 in this case) to
access of the methyl group in the deep crevice is indis-
pensable for methylation. Further, Lys372 methylation
is shown to partially block the Smyd2-p53 interaction
(Huang et al., 2006). Taking together, the current data
also highlight the molecular basis for the inhibition of
Lys370 methylation by monomethylated Lys372.
To extract representative conformers that can better
explain the conformational rearrangements, density-
based clustering analysis was performed based on the
peptide structural properties (Fig. S7). The representa-
tive conformers, extracted from the high dense regions,
are reported in Fig. 5E. The conformers are well
superimposed between positions 1 to +2 (Leu369–
Lys372) except at the terminals with high degree of
difference at the C-terminal end that engages in inter-
actions with the Smyd2 CTD. This result agrees with
the larger flexibility observed for this region
(vide supra). It is also worth to note that the U-shaped
conformation of the peptide is well maintained as
observed in the X-ray structure.
The comparison of Smyd2 structures in complex with
ERa and p53 peptides showed that both peptides adopt
similar U-shaped conformation, the respective target lysi-
nes being similarly orientated toward the cofactor (Jiang
et al., 2014). However, structural difference was observed
at residues spanning beyond +3 positions from the target
lysine, interacting with distinct residues in the CTD. In
line, representative conformers, reported here, show
notable difference toward the C-terminal ends. This
explains the role of the CTD in substrate stabilization
via characteristics interactions.
4. Conclusions
The p53 is the most frequently mutated gene in cancer,
reaching a median frequency of 50% mutation rate in all
cancers. This results in gain-of-function deregulation of
the DNA damage response (Vaughan et al., 2017; Zache
et al., 2017), fostering tumor progression (Bartek et al.,
2017; Fang et al., 2018), for example, by deregulating its
apoptotic targets (Goiran et al., 2018; Sharma et al.,
2018), metabolic enzymes (Moon et al., 2019; Sorrentino
et al., 2018; Xu et al., 2018), or the AMPK pathway
(Houde et al., 2017). Understanding these mechanisms is
essential to explore innovative therapeutic venues (Hasna
et al., 2018; Malgerud et al., 2017; Siebring-van Olst et al.,
2017). At the molecular level, p53 physically binds several
targets, such as, for example, MDM2 and MDMX (Arena
et al., 2018; Soares et al., 2017) or indeed Smyd2 (Wang
et al., 2011). Based on the structural insights on p53 (Joer-
ger and Fersht, 2008, 2016), we have therefore investigated
the interaction between p53 and Smyd2.
Thanks to the availability of a supercomputer, we
have performed an unusual long MD analysis, up to
four l-second total simulated time. The data shown
above sustain the conclusion that the C-terminal domain
of Smyd2 (a) has a degree of conformational freedom
that is restricted by the physical interaction with the p53
peptide substrate, and (b) shows distinct dynamic proper-
ties when interacting with unmethylated and methylated
p53 peptides. In turn, (c) the p53 peptide is conforma-
tionally confined by Lys372 methylation, which also
noticeably affects the Lys370 accessibility to the cofactor.
These MD results further expand the knowledge of the
p53 biology at the molecular level.
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